Xencor Inc (XNCR)
19.98
+0.75
(+3.90%)
USD |
NASDAQ |
Apr 26, 16:00
19.96
-0.02
(-0.10%)
After-Hours: 20:00
Xencor Enterprise Value: 602.93M for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 25, 2024 | 602.93M |
April 24, 2024 | 590.09M |
April 23, 2024 | 550.37M |
April 22, 2024 | 540.59M |
April 19, 2024 | 550.98M |
April 18, 2024 | 585.82M |
April 17, 2024 | 593.15M |
April 16, 2024 | 583.98M |
April 15, 2024 | 656.72M |
April 12, 2024 | 679.33M |
April 11, 2024 | 681.77M |
April 10, 2024 | 666.49M |
April 09, 2024 | 744.73M |
April 08, 2024 | 741.67M |
April 05, 2024 | 728.84M |
April 04, 2024 | 733.73M |
April 03, 2024 | 742.89M |
April 02, 2024 | 742.28M |
April 01, 2024 | 767.34M |
March 28, 2024 | 780.18M |
March 27, 2024 | 797.90M |
March 26, 2024 | 743.51M |
March 25, 2024 | 766.12M |
March 22, 2024 | 810.13M |
March 21, 2024 | 821.74M |
Date | Value |
---|---|
March 20, 2024 | 818.07M |
March 19, 2024 | 818.68M |
March 18, 2024 | 787.51M |
March 15, 2024 | 838.85M |
March 14, 2024 | 774.07M |
March 13, 2024 | 855.36M |
March 12, 2024 | 821.13M |
March 11, 2024 | 841.30M |
March 08, 2024 | 909.75M |
March 07, 2024 | 881.64M |
March 06, 2024 | 884.08M |
March 05, 2024 | 824.18M |
March 04, 2024 | 889.58M |
March 01, 2024 | 883.47M |
February 29, 2024 | 830.30M |
February 28, 2024 | 820.52M |
February 27, 2024 | 1.048B |
February 26, 2024 | 1.009B |
February 23, 2024 | 923.20M |
February 22, 2024 | 918.31M |
February 21, 2024 | 899.97M |
February 20, 2024 | 863.91M |
February 16, 2024 | 903.64M |
February 15, 2024 | 729.45M |
February 14, 2024 | 653.65M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
511.74M
Minimum
Nov 09 2023
2.515B
Maximum
Feb 08 2021
1.353B
Average
1.345B
Median
Enterprise Value Benchmarks
Ionis Pharmaceuticals Inc | 5.050B |
Karyopharm Therapeutics Inc | 101.45M |
NovaBay Pharmaceuticals Inc | 2.275M |
Palatin Technologies Inc | 18.27M |
iBio Inc | 15.86M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -19.10M |
Revenue (Quarterly) | 44.69M |
Total Expenses (Quarterly) | 79.70M |
EPS Diluted (Quarterly) | -0.31 |
Profit Margin (Quarterly) | -42.74% |
Earnings Yield | -10.52% |
Normalized Earnings Yield | -10.25 |